Roles of biomarkers in <scp>anti‐MDA5</scp>‐positive dermatomyositis, associated interstitial lung disease, and rapidly progressive interstitial lung disease

Li, Xiaomeng; Liu, Yongmei; Cheng, Linlin; Huang, Yuan; Yan, Songxin; Li, Haolong; Zhan, Haoting; Li, Yongzhe

doi:10.1002/jcla.24726

Cited by 8 publications

(4 citation statements)

References 112 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…12 Tumor markers and ferritin are elevated in dermatomyositisrelated RP-ILD, and serum CA-153 levels can evaluate disease severity and be used as a prognostic marker in anti-MDA-5 positive patients. 13,14 In Figure 3…”

Section: Discussionmentioning

confidence: 99%

Tofacitinib treatment in anti‐glycyl‐tRNA synthetase antibody interstitial lung disease – A case report

Tseng

2022

Int J of Rheum Dis

View full text Add to dashboard Cite

Anti-aminoacyl-transfer-RNA synthetase syndrome (ASS) related interstitial lung disease (ILD) is rarely presented initially alongside acute respiratory distress syndrome (ARDS), which in and of itself is a severe condition with a high mortality rate.Additionally, rapidly progressive change is not a common feature in ASS. Numerous case reports have described the efficacy which tofacitinib has on rapidly progressive ILD (RP-ILD). However, none have mentioned the use of tofacitinib in patients with impaired renal function. Herein, a case of ASS involving ILD is reported with the initial presentation of RP-ILD to ARDS being complicated by acute renal failure with an initial complete response to tofacitinib. Patients experiencing unexplained rapidly progressive interstitial pneumonia should be examined thoroughly for the diagnosis of ASS. Furthermore, tofacitinib can also be considered as a choice of treatment even in patients with impaired renal function.

show abstract

Section: Discussionmentioning

confidence: 99%

Tofacitinib treatment in anti‐glycyl‐tRNA synthetase antibody interstitial lung disease – A case report

Tseng

2022

Int J of Rheum Dis

View full text Add to dashboard Cite

show abstract

“…The prevalence of anti-MDA5 antibodies in DM ranges from 7–60%, with a prevalence higher in Asians (11–60%) than in whites (7–16%) [40 ▪ ]. In most studies, anti-MDA5 ILD is more common, more severe and rapidly progressive comparing to anti-ARS-antibody ILD or nonanti-MDA5 ILD [41,42]. Clinical features of anti-MDA5 dermatomyositis include skin involvement similar to dermatomyositis (Fig.…”

Section: Anti-synthetase Syndromementioning

confidence: 99%

Myositis-associated interstitial lung disease

Trang

Brown

Solomon

2023

Current Opinion in Pulmonary Medicine

View full text Add to dashboard Cite

Purpose of review In idiopathic inflammatory myopathies (IIMs), interstitial lung disease (ILD) is common and the autoantibody profile, made up of myositis-specific and myositis-associated (MSA and MAA) antibodies, can predict the clinical phenotype and progression over time. This review will focus on the characteristics and management of antisynthetase syndrome related ILD and anti-MDA5 positive ILD, which are the most clinically relevant subtypes. Recent findings The prevalence of ILD in IIM has been estimated in Asia, North America and Europe at 50, 23 and 26%, respectively, and is increasing. In antisynthetase syndrome related ILD, the clinical presentation, progression and prognosis varies among anti-ARS antibodies. ILD is more common and severe in patients with anti-PL-7/anti-PL-12 antibodies when compared with anti Jo-1 patients. The prevalence of anti-MDA5 antibodies is higher in Asians (11–60%) than in whites (7–16%). Sixty-six percent of antisynthetase syndrome patients had ‘chronic ILD’ compared with the more rapidly progressive ILD (RP-ILD) seen in 69% of patients with anti-MDA5 antibodies. Summary ILD is most common in the antisynthetase subtype of IIM and can be a chronic indolent or RP- ILD. The MSA and MAAs are associated with different clinical phenotypes of ILD. Treatments typically involve combinations of corticosteroids and other immunosuppressants.

show abstract

“…Onset of RP‐ILD followed less intense ILD that was not responsive to initial therapy in 3 patients. All developed RP‐ILD within 6 months of disease onset with concerning laboratory abnormalities 4,6–11 . All 4 patients were febrile, an important clinical indicator for developing RP‐ILD and also mortality.…”

Section: Ethnic/clinical Autoantibodiesmentioning

confidence: 99%

“…All developed RP-ILD within 6 months of disease onset with concerning laboratory abnormalities. 4,[6][7][8][9][10][11] All 4 patients were febrile, an important clinical indicator for developing RP-ILD and also mortality. Three of the 4 patients had elevated ferritin levels with 2 of the 4 having levels over 1000 ng/mL, a key predictor of RP-ILD and mortality that likely reflects macrophage activation.…”

mentioning

confidence: 99%

Treating dermatomyositis anti‐melanoma differentiation‐associated gene 5 antibody disease. A true rheumatologic urgency

Gardner

2023

Int J of Rheum Dis

View full text Add to dashboard Cite

Treating dermatomyositis anti-melanoma differentiationassociated gene 5 antibody disease. A true rheumatologic urgencyWhen the anti-melanoma differentiation-associated gene 5 (MDA5) antibody is detected in a patient with dermatomyositis (DM) it is cause for concern because of the propensity of developing rapidly progressive interstitial lung disease (RP-ILD). RP-ILD occurs in 39%-92% of MDA5-DM patients with a mortality rate historically at 50%. 1 In a series of 121 patients with MDA5 disease, 80% of RP-ILD patients died within 3 months of diagnosis. 2 Truly anxietyprovoking numbers! Li et al 3 defined RP-ILD as "a rapidly progressive dyspnea and hypoxemia with a worsening of radiologic interstitial lung changes within 3 months after the onset of respiratory symptoms". RP-ILD typically developments in the first 6-12 months from the onset of MDA5-DM. 4 Recently Tseng published a report on 4 patients in the International Journal of Rheumatic Diseases with MDA5-RP-ILD and included a treatment flow diagram that brings up key issues in MDA5 disease. 5 Since the series was from Taiwan it is likely these patients

show abstract

Roles of biomarkers in anti‐MDA5‐positive dermatomyositis, associated interstitial lung disease, and rapidly progressive interstitial lung disease

Cited by 8 publications

References 112 publications

Tofacitinib treatment in anti‐glycyl‐tRNA synthetase antibody interstitial lung disease – A case report

Tofacitinib treatment in anti‐glycyl‐tRNA synthetase antibody interstitial lung disease – A case report

Myositis-associated interstitial lung disease

Treating dermatomyositis anti‐melanoma differentiation‐associated gene 5 antibody disease. A true rheumatologic urgency

Contact Info

Product

Resources

About